DEVELOPMENT OF AN ORAL FORMULATION AND TOXICITY STUDIES FOR INHIBITOR, WP1066, OF THE SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 – A PATHWAY THAT DRIVES THE DEVELOPMENT OF MALIGNANT BRAIN TUMORS AND IMMUNE SUPPRESSION.

PIs: Amy Heimberger, M.D.
Professor, Neurosurgery
MD Anderson Cancer Center

Waldemar Priebe, M.Sc., Ph.D.
Professor, Experimental Therapeutics Department
MD Anderson Cancer Center

Charles A. Conrad, M.D.
Professor, Neuro-Oncology
MD Anderson Cancer Center